Human microbiome therapeutics use beneficial microorganisms, their byproducts, or microbiome-modulating therapies to treat or prevent disease by restoring a healthy microbial balance. The human microbiome, made up of trillions of bacteria, viruses, fungi, and other microbes, plays a crucial role in digestion, immunity, metabolism, and even mental health. Polaris Market Research reports that the human microbiome therapeutics market was valued at USD 1.01 billion in 2024 and is growing at a CAGR of 22.80% from 2025 to 2034. The 2025 market estimate is USD 1.24 billion, rising to a projected USD 7.89 billion by 2034, with North America the largest market in 2024.

Therapeutic Approaches Gaining Attention

Microbiome therapeutics include postbiotics and fecal microbiota transplantation, in which healthy donor microbes are transplanted to restore gut flora. More advanced approaches involve engineered bacteria, phage therapy, and microbiome-targeted drugs. Polaris notes that these therapies are being used to treat infections, metabolic disorders, allergies, and even cancer by enhancing immune responses. Imbalances in the gut microbiota are contributing to gastrointestinal diseases, and pharmaceutical companies and researchers are investing heavily in microbiome therapies, responding to the need for targeted interventions that address root causes.

Two Demand Drivers for Industry Stakeholders

First, the high prevalence of chronic diseases such as diabetes, obesity, cardiovascular disorders, and autoimmune conditions is fueling demand, as research increasingly links gut microbiota imbalances to these conditions. The report cites the World Health Organization's figure that noncommunicable diseases caused at least 43 million deaths in 2021. Second, the growing focus on personalized medicine is boosting demand because each individual's microbiome is unique, influencing disease progression and treatment response. Advances in genomic sequencing and AI-driven analytics now enable deeper insight into microbiome-disease interactions, making these therapies a key component of precision medicine strategies. Ongoing cancer research is expected to create a lucrative opportunity, although the lack of robust clinical data and awareness hinders market growth.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market

Indication and Product Pipeline Insights

By indication, Clostridium difficile infection dominated revenue in 2024 because of high recurrence rates, growing antibiotic resistance, and the urgent need for alternatives to conventional antimicrobial therapies. Clinicians increasingly adopted interventions such as fecal microbiota transplantation and live biotherapeutics for their ability to restore healthy gut flora and reduce reinfection risk. The rising incidence of hospital-acquired infections, combined with strong regulatory support for innovative treatment approaches, accelerated product development in this segment. Polaris also points to the expansion of live biotherapeutic product pipelines as a benefit for the wider market.

Regional Outlook and Industry Activity

North America accounted for 48.15% of global revenue in 2024, attributed to rising incidences of chronic diseases such as obesity and diabetes. According to the CDC, 6 in 10 Americans have at least one chronic disease, and 4 in 10 have two or more. The U.S. held the largest share within the region, supported by strong biotech investment and an evolving FDA regulatory framework that backed clinical trials for microbiome-based drugs. Asia Pacific is projected to grow at the fastest pace, owing to increasing healthcare awareness and rising disposable incomes, with China, Japan, and India investing heavily in microbiome research. In June 2025, Seed Health, Inc. announced the nationwide retail rollout of its microbiome products across approximately 450 Sprouts locations in 24 U.S. states. Germany's demand is driven by a strong pharmaceutical industry and advanced research in gut microbiota.

Key Players

•         Enterome SA

•         Ferring Pharmaceuticals

•         Finch Therapeutics Group Inc.

•         Locus Biosciences Inc.

•         MaaT Pharma

•         Microbiotica Ltd

•         Osel Inc.

•         Seres Therapeutics Inc.

•         Synlogic Inc.

•         Vedanta Biosciences

Conclusion

The human microbiome therapeutics market is moving from promising science toward commercial reality. Valued at USD 1.01 billion in 2024 and projected to reach USD 7.89 billion by 2034 at a CAGR of 22.80%, it is supported by chronic disease burden, personalized treatment strategies, and growing clinical experience in recurrent infections. Pharmaceutical and biotech stakeholders should track clinical evidence, regulatory direction, and regional momentum, particularly in Asia Pacific, as the field matures.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market